26.98

1.16% 0.31

Newamsterdam Pharma Company Nv (NAMS)

Overview News Price History Financials Why NAMS Down? Discussions Forecast

Newamsterdam Pharma Company Nv stock is traded at $26.98, with a volume of 959.59K. It is up +1.16% in the last 24 hours and down -18.95% over the past month. NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Previous Close:

$26.67

Open:

$26.26

24h Volume:

959.59K

Relative Volume:

0.80

Market Cap:

$3.23B

Revenue:

$22.57M

Net Income/Loss:

$-212.73M

P/E Ratio:

-14.95

EPS:

-1.8045

Net Cash Flow:

$-142.19M

1W Performance:

-3.51%

1M Performance:

-18.95%

6M Performance:

-22.09%

1Y Performance:

+7.19%

1-Day Range:

$26.01

$27.06

1-Week Range:

$26.01

$28.97

52-Week Range:

$23.05

$42.20

Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile

Name

Newamsterdam Pharma Company Nv

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

35 206 2971

Address

GOOIMEER 2-35, NARRDEN

Employee

100

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

NAMS's Discussions on Twitter

Compare NAMS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NAMS Newamsterdam Pharma Company Nv	26.98	3.33B	22.57M	-212.73M	-142.19M	-1.8045
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Oct-20-25	Resumed	H.C. Wainwright	Buy
Aug-25-25	Initiated	Wells Fargo	Overweight
Jul-17-25	Initiated	Goldman	Neutral
Jun-17-25	Initiated	Citigroup	Buy
Jun-10-25	Initiated	Stifel	Buy
Jun-04-25	Initiated	Cantor Fitzgerald	Overweight
Dec-30-24	Initiated	H.C. Wainwright	Buy
May-15-24	Initiated	TD Cowen	Buy
Mar-14-24	Initiated	Scotiabank	Sector Outperform
Jan-18-24	Initiated	Guggenheim	Buy
Jan-16-24	Initiated	Piper Sandler	Overweight
Oct-30-23	Initiated	RBC Capital Mkts	Outperform

View All

Newamsterdam Pharma Company Nv Stock (NAMS) Latest News

Aug 14, 2026

NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal - Stock Titan

Aug 14, 2026

NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer - Stock Titan

Aug 14, 2026

Aug 11, 2026

How Newamsterdam Pharma Company N.v. (NAMS) Affects Rotational Strategy Timing - Stock Traders Daily

Aug 11, 2026

Did NewAmsterdam Pharma’s (NAMS) Sharp Revenue Drop and Wider Loss Just Shift Its Investment Narrative? - simplywall.st

Aug 11, 2026

Aug 10, 2026

HC Wainwright Issues Pessimistic Outlook for NAMS Earnings - MarketBeat

Aug 10, 2026

Aug 07, 2026

Equities Analysts Offer Predictions for NAMS FY2027 Earnings - MarketBeat

Aug 07, 2026

Aug 06, 2026

NewAmsterdam Pharma grants 28,000 inducement share options at $27.79 to new hires - Bitget

Aug 06, 2026

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Aug 06, 2026

(NAMSW) Volatility Zones as Tactical Triggers - Stock Traders Daily

Aug 06, 2026

FMR LLC and Abigail Johnson report 10.3M-share Pharma Company NV (NAMS) stake - Stock Titan

Aug 06, 2026

Aug 05, 2026

NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 05, 2026